GlassScriptPhysician profile
Harprabhjit Singh
NPI 1588783062
$4,447.87
in general payments reported to CMS, 2019-2025
22 companies · $700 in 2025
The $700 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $497 · 2020: $257 · 2021: $483 · 2022: $738 · 2023: $953 · 2024: $819 · 2025: $700.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,386 · Education: $85.44.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,386.38 |
| Education | $85.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,236.40 | 2019-2025 | Rinvoq, Skyrizi, Mavyret |
| Janssen Biotech, INC. | $661.03 | 2019-2025 | Stelara, Tremfya, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $476.88 | 2019-2025 | Entyvio, Eohilia |
| Celgene Corporation | $454.46 | 2021-2024 | Zeposia |
| Gilead Sciences, INC. | $436.98 | 2019-2025 | Livdelzi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $358.24 | 2019-2023 | Xifaxan |
| Phathom Pharmaceuticals, INC. | $138.60 | 2023-2024 | Voquezna |
| Intercept Pharmaceuticals, INC. | $124.57 | 2019-2024 | Ocaliva |
| Madrigal Pharmaceuticals | $96.23 | 2024-2025 | Rezdiffra, Resmetirom |
| Braintree Laboratories, INC. | $93.16 | 2019-2024 | Sutab, Suflave |
| Pfizer INC. | $72.55 | 2019-2024 | |
| Genzyme Corporation | $47.24 | 2023-2024 | |
| Regeneron Healthcare Solutions, INC. | $43.67 | 2024-2025 | Dupixent |
| Ironwood Pharmaceuticals, INC | $40.42 | 2020-2021 | |
| Ipsen Biopharmaceuticals, INC | $38.62 | 2024-2025 | Iqirvo, Bylvay |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shionogi INC | $26.63 | 2019 | |
| Qol Medical, LLC | $20.75 | 2025 | Sucraid |
| Lilly USA, LLC | $18.53 | 2025 | Omvoh |
| Daiichi Sankyo INC. | $16.67 | 2020 | |
| Nestle Healthcare Nutrition INC. | $16.56 | 2021 | |
| Novo Nordisk INC | $15.74 | 2025 | Wegovy |
| Ucb, INC. | $13.94 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Harprabhjit Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.